Biomedical Engineering Reference
In-Depth Information
[325] Scharfmann R, Axelrod JH, Verma IM. Long-term
in vivo
expression of retrovirus-
mediated gene transfer in mouse fibroblast implants. Proc Natl Acad Sci USA 1991;88:
4626-30.
[326] Kay MA, Rothenberg S, Landen CN, Bellinger DA, Leland F, Toman C, et al.
In vivo
gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs.
Science 1993;262:117-19.
[327] Xu L, Gao C, Sands MS, Cai SR, Nichols TC, Bellinger DA, et al. Neonatal or hepa-
tocyte growth factor-potentiated adult gene therapy with a retroviral vector results in
therapeutic levels of canine factor IX for hemophilia B. Blood 2003;101:3924-32.
[328] Smith TA, Mehaffey MG, Kayda DB, Saunders JM, Yei S, Trapnell BC, et al.
Adenovirus mediated expression of therapeutic plasma levels of human factor IX in
mice. Nat Genet 1993;5:397-402.
[329] Roth DA, Tawa Jr NE, O'Brien JM, Treco DA, Selden RF. Factor VIII transkaryotic
therapy study group. Nonviral transfer of the gene encoding coagulation factor VIII in
patients with severe hemophilia A. N Engl J Med 2001;344:1735-42.
[330] Powell JS, Ragni MV, White GC, Lusher JM, Hillman-Wiseman C, Moon TE, et al.
Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct
administered by peripheral intravenous infusion. Blood 2003;102:2038-45.
[331] Chua MKL, Collen D, Vanden Driessche T. Clinical gene transfer studies for
Hemophilia A. Semin Thromb Hemostasis 2004;30:249-56.
[332] High KA. Clinical gene transfer studies for hemophilia B. Semin Thromb Hemostasis
2004;30:257-67.
Search WWH ::
Custom Search